ATE401074T1 - Synergistische antibakterielle formulierung und herstellungsmethode - Google Patents

Synergistische antibakterielle formulierung und herstellungsmethode

Info

Publication number
ATE401074T1
ATE401074T1 AT05250879T AT05250879T ATE401074T1 AT E401074 T1 ATE401074 T1 AT E401074T1 AT 05250879 T AT05250879 T AT 05250879T AT 05250879 T AT05250879 T AT 05250879T AT E401074 T1 ATE401074 T1 AT E401074T1
Authority
AT
Austria
Prior art keywords
manufacturing
synergistic antibacterial
formulation
antibacterial formulation
cloxacillin sodium
Prior art date
Application number
AT05250879T
Other languages
English (en)
Inventor
Sanjeev Khandelwal
Original Assignee
Sanjeev Khandelwal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanjeev Khandelwal filed Critical Sanjeev Khandelwal
Application granted granted Critical
Publication of ATE401074T1 publication Critical patent/ATE401074T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05250879T 2004-02-16 2005-02-16 Synergistische antibakterielle formulierung und herstellungsmethode ATE401074T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN178MU2004 2004-02-16
IN258MU2004 2004-03-03

Publications (1)

Publication Number Publication Date
ATE401074T1 true ATE401074T1 (de) 2008-08-15

Family

ID=34712743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05250879T ATE401074T1 (de) 2004-02-16 2005-02-16 Synergistische antibakterielle formulierung und herstellungsmethode

Country Status (5)

Country Link
US (1) US7632520B2 (de)
EP (1) EP1566176B1 (de)
AT (1) ATE401074T1 (de)
CY (1) CY1108417T1 (de)
DE (1) DE602005008122D1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
WO2013109228A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Formulations comprising cefixime as active agent
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN110917220A (zh) 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
EP3904502A3 (de) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Zusammensetzungen und verfahren
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
RU2722482C2 (ru) 2013-11-25 2020-06-01 Серес Терапеутикс, Инк. Синергические бактериальные композиции и способы их получения и применения
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
CN115025066B (zh) * 2021-05-25 2023-05-16 重庆市畜牧科学院 一种质量稳定的抗仔猪腹泻中药缓释颗粒的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6483025A (en) * 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
IN183097B (de) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
PL193929B1 (pl) * 1998-03-23 2007-04-30 Gen Mills Inc Jadalny produkt na bazie skrobi, kompozycja odżywcza oraz sposób wytwarzania jadalnego produktu
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof

Also Published As

Publication number Publication date
DE602005008122D1 (de) 2008-08-28
EP1566176A1 (de) 2005-08-24
CY1108417T1 (el) 2014-04-09
US7632520B2 (en) 2009-12-15
US20050181051A1 (en) 2005-08-18
EP1566176B1 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
ATE401074T1 (de) Synergistische antibakterielle formulierung und herstellungsmethode
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ZA200500734B (en) Microcapsules with modified release of active principles with law solubility for oral delivery
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
AR053680A1 (es) Composicion
EA200800950A1 (ru) Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
GT200500318A (es) Formulaciones de derivados de [1.4]diazepina[6,7,1-ij]quinolina
BG108516A (en) Pharmaceutical formulation
BRPI0407181A (pt) Formulação farmacêutica
ATE392889T1 (de) Orale antimikrobielle pharmazeutische zusammensetzungen
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
WO2005030109A3 (en) Regimen for the administration of rifamycin-class antibiotics
WO2008057196A3 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
MX2007005980A (es) Composiciones para el tratamiento de infecciones oticas.
BR0210632A (pt) Tratamento de doença parasìtica
MA27689A1 (fr) Forme galenique orale pour la liberation controlee de medicament
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE395043T1 (de) Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung
EA200800733A1 (ru) Фармацевтический хитозановый наполнитель для применения в твёрдых лекарственных формах
AU2003202550A1 (en) Pharmaceutical formulations with modified release
UY31541A1 (es) 1(2)h-tetrazol-5-il-fenil-oxazolidinona s como agentes antibacterianos
BRPI0411524A (pt) formulação farmacêutica de amoxicilina e clavulanato, uso de carboximetilcelulose de sódio, e, método de tratar infecção bacteriana em pacientes pediátricos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties